Are Shareholders of ACLX, MASI, and FONR Being Treated Justly in Recent Sales? Halper Sadeh LLC is probing three companies, ACLX, MASI, and FONR, for possible breaches of fiduciary duties that could harm shareholders. Learn more.

Are Shareholders of ACLX, MASI, and FONR Being Treated Justly in Recent Sales? #USA #New_York #Halper_Sadeh #ACLX #MASI

Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders? {"summary":"","positive":[],"negative":[],"faq":[]}

#ACLX #FONR #MASI Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?

www.stocktitan.net/news/ACLX/are-aclx-masi-...

Investigating Potential Securities Violations in MASI, ACLX, and GLDD Sales Halper Sadeh LLC is probing MASI, ACLX, and GLDD for possible breaches of fiduciary duty related to their sales. Shareholders may be entitled to further benefits.

Investigating Potential Securities Violations in MASI, ACLX, and GLDD Sales #United_States #New_York #Halper_Sadeh #ACLX #MASI

Investigation into Fairness of Shareholder Deals Involving ACLX, VRE, and LSF Halper Sadeh LLC explores potential breaches of fiduciary duties in transactions involving ACLX, VRE, and LSF, ensuring shareholder rights are protected.

Investigation into Fairness of Shareholder Deals Involving ACLX, VRE, and LSF #USA #New_York #VRE #LSF #ACLX

📢 Stocks Trending NOW: #NVO #LLY #VNDA #NOVO-B.CO #DPZ #ACLX #IBRX #GOSS #D #TIRX

💥 #ACLX = +80% #GILD = -1%

Gilead to buy cancer drug developer Arcellx for up to $7.8bn

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BYND, #FLEX, #MDLN, #LUNR, #ACLX

#OptionFlow #OptionsTrading #Trading

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma Arcellx (NASDAQ: ACLX) reported updated pivotal Phase 2 iMMagine-1 results for anitocabtagene autoleucel (anito-cel) in 117 relapsed/refractory multiple myeloma patients with a median follow-up of 15.9 months (data cutoff Oct 7, 2025).Key efficacy: ORR 96%, CR/sCR 74%, ≥VGPR 88%; MRD negativity 95% (91/96) and sustained MRD negativity >6 months 83% (54/65) at 10-5 sensitivity. Timepoint survival: 12‑month PFS/OS 82.1%/94.0%, 18‑month PFS/OS 67.4%/88.0%, 24‑month PFS/OS 61.7%/83.0%.Safety: no delayed or non‑ICANS neurotoxicities observed to date (all patients dosed ≥12 months). Company reiterates planned 2026 commercial launch. Data presented at ASH on December 6, 2025.

#ACLX Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

www.stocktitan.net/news/ACLX/arcellx-announ...

Breakthrough: Arcellx Multiple Myeloma Drug Achieves 97% Response Rate, FDA Clears New Cancer Program New clinical data reveals 97% response rate for Arcellx's multiple myeloma therapy. $538M cash runway through 2028, FDA clearance for new cancer program. See full results.

#ACLX Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/ACLX/arcellx-provid...

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 Arcellx (NASDAQ: ACLX), a biotechnology company focused on developing innovative cell therapy immunotherapies, has announced its participation in two upcoming investor events. The company will present at TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 9:00 a.m. PT in a virtual format. Additionally, Arcellx will host a management and physician presentation discussing the iMMagine-1 Pivotal Study Results during EHA2025 on June 13, 2025, at 8:30 p.m. CEST, both virtually and in-person in Milan, Italy. Both events will be accessible via webcast on the company's website and will remain available for 30 days after the events.

#ACLX Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

www.stocktitan.net/news/ACLX/arcellx-announ...

New Multiple Myeloma Treatment Achieves 97% Response Rate with Zero Delayed Neurotoxicity in Phase 2 Trial Breakthrough Phase 2 results reveal 97% response rate and clean safety profile for multiple myeloma therapy. Key efficacy data exceeds expectations. See full results.

#ACLX Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

www.stocktitan.net/news/ACLX/arcellx-announ...

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights Arcellx (NASDAQ: ACLX) reported its Q1 2025 financial results and business updates. The company's iMMagine-1 trial data has been accepted for oral presentation at the European Hematology Association Congress on June 14, 2025. A significant protocol update to the iMMagine-3 study now includes Minimal Residual Disease negativity as a dual primary endpoint alongside progression-free survival. The company strengthened its board with two new members: Andrew Galligan and Kristin Myers, bringing commercial and operational expertise. Financially, Arcellx reported $565.2 million in cash reserves, expected to fund operations into 2028. Q1 2025 results showed collaboration revenue of $8.1 million (down from $39.3M in Q1 2024), R&D expenses of $50.8 million (up from $32.3M), and a net loss of $62.3 million (compared to $7.2M loss in Q1 2024).

#ACLX Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/ACLX/arcellx-provid...

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights Arcellx (NASDAQ: ACLX) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its anito-cel treatment for relapsed/refractory multiple myeloma (RRMM). The Phase 2 pivotal iMMagine-1 study showed impressive results with a 97% overall response rate and 62% complete response rate in 86 patients at 9.5 months median follow-up.Key financial metrics include $625.7 million in cash and equivalents, providing runway into 2027. Q4 collaboration revenue was $15.3 million, down from $63.1 million in Q4 2023. Full-year net loss increased to $107.3 million from $70.7 million in 2023.The company plans to commercially launch anito-cel in 2026 and will present updated iMMagine-1 data mid-2025. Notably, no delayed neurotoxicities were observed in 155 patients across Phase 1 and iMMagine-1 studies.

#ACLX Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

www.stocktitan.net/news/ACLX/arcellx-provid...